Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
+6
Published on September 10
Major pharmaceutical companies are restructuring and competing fiercely, creating opportunities for innovative players to capture market share or become acquisition targets.
Companies developing oral medications and alternative delivery methods could revolutionise the weight-loss drug market with more convenient treatment options.
As competition intensifies, larger pharmaceutical companies may seek to acquire innovative biotech firms to strengthen their obesity treatment portfolios.
The weight-loss drug market is experiencing unprecedented competition as Novo Nordisk restructures to combat rivals like Eli Lilly. This intense rivalry creates opportunities for innovative pharmaceutical companies developing next-generation treatments or alternative delivery methods that could capture market share or become attractive acquisition targets.
This group includes both established pharmaceutical giants investing heavily in obesity treatments and smaller biotech firms developing novel therapies. The sector offers high growth potential driven by clinical breakthroughs and M&A activity, though it carries the typical risks associated with drug development and regulatory approval processes.
These companies were handpicked by professional analysts for their strategic positioning in the evolving weight-loss drug landscape. They represent a mix of market leaders, innovative pipeline developers, and potential acquisition targets that could benefit from the sector's growth and consolidation trends.
Market capitalisation breakdown for a basket focused on obesity treatment, showing dominance of large-cap pharmaceutical firms versus smaller biotech names.
NVO: $180.85B
LLY: $756.76B
PFE: $141.29B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+89.43%
On average, analysts expect assets in this group to grow 89.43% over the next year.
12 of 15 assets in this group are rated Buy by professional analysts.
